• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Integer to Showcase Strategic Investments to Support Customers' Growth and Innovation at Heart Rhythm 2024

    5/7/24 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email

    PLANO, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), will join medtech industry leaders around the world in exhibiting at Heart Rhythm 2024, a Heart Rhythm Society (HRS) educational event and exhibition in Boston from May 16 – 19, 2024.

    HRS attendees are invited to visit Integer at booth #753 to learn more about the company's comprehensive end-to-end solutions, designed to help customers accelerate time to market, strengthen innovation, simplify supply chain and confidently scale production across a globally competitive network of locations.

    Some examples include market-leading battery technology, finished leads and implantable pulse generators (IPG) for cardiac applications. Integer is a leading manufacturer of access and complex catheter access solutions in electrophysiology, including guidewires, transseptal access, diagnostic and ablation technology platforms.

    Those attending HRS will discover how Integer's recent strategic investments, particularly the acquisition of Pulse Technologies, are reshaping how Integer serves the world's leading medical device OEMs and start-ups. Pulse Technologies, based in Quakertown, Pennsylvania, brings unmatched precision machining and patented technologies such as Hierarchical Surface Restructuring (HSR™) coatings to Integer's portfolio. These innovations significantly enhance the performance and reliability of medical devices across cardiac rhythm management, neuromodulation, and cardiovascular applications. HSR enhances electrodes and microelectrode arrays using a proprietary ultra-short pulse laser-based process, supporting a range of applications.

    "The integration of Pulse Technologies' advanced surface texturing and coating technologies into Integer's services empowers the development of specialized components that offer superior electrochemical performance and durability," said Payman Khales, President, Cardio & Vascular.

    Khales added, "These capabilities allow Integer to support the rapidly evolving needs of the medical device sector with innovative solutions that significantly shorten time to market and enhance patient care."

    Learn more about Integer at www.integer.net.

    About Integer®

    Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

    Investor Relations:

    Andrew Senn

    [email protected]

    763.951.8312
    Media Relations:

    Kelly Butler

    [email protected]

    469.731.6617





    Primary Logo

    Get the next $ITGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    2/20/2026$95.00Hold → Buy
    The Benchmark Company
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    More analyst ratings

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer to Participate at Upcoming Investor Conferences

    PLANO, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that members of its executive leadership team will participate in the following investor conferences in March: Raymond James 47th Annual Institutional Investors Conference, 11:35 a.m. ET, March 3Oppenheimer 36th Annual Healthcare MedTech & Services Conference, 12:40 p.m. ET, March 17KeyBanc Capital Markets Healthcare Forum, 11:15 a.m. ET, March 18 A live webcast and replay for each event will be accessible under "News & Events" on the Investor Relations section of Integer's website at investor.integer.net.

    2/24/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2025

    ~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise stated, all results and comparisons are from continuing operations. Fourth Quarter 2025 Financial Results (compared to fourth quarter 2024, except as noted) Sales increased 5% to $472 mill

    2/19/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Integer Holdings Corporation

    SCHEDULE 13G/A - Integer Holdings Corp (0001114483) (Subject)

    3/27/26 9:55:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Integer Holdings Corporation

    8-K - Integer Holdings Corp (0001114483) (Filer)

    3/12/26 8:02:27 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Integer Holdings Corporation

    10-K - Integer Holdings Corp (0001114483) (Filer)

    2/23/26 8:03:27 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Ops and Manufactur Harris John A bought $115,500 worth of shares (1,650 units at $70.00), increasing direct ownership by 37% to 6,066 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/13/25 4:18:50 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Integer Holdings from Hold to Buy and set a new price target of $95.00

    2/20/26 8:20:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kapito Aaron

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:52 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Carr Terence

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:47 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Flanagan James Francis

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:42 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints Michael Coyle to Board of Directors

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2025

    ~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise stated, all results and comparisons are from continuing operations. Fourth Quarter 2025 Financial Results (compared to fourth quarter 2024, except as noted) Sales increased 5% to $472 mill

    2/19/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care